Wire · operational-macro
FDA grants fast track designation to VIR-5500 for mCRPC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
The FDA has granted fast track designation to VIR-5500, a PSMA-targeted dual-masked T-cell engager developed by Vir Biotechnology and Astellas Pharma for late-line metastatic castration-resistant prostate cancer. The designation enables more frequent FDA engagement and eligibility for accelerated approval, with phase 3 trials expected to start in 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 8 Oct 2026 and 9 Oct 2026.
◆ ◆ The Wire takeaway
You have a rare FDA-fast-track slot opening that speeds review and pushes safety dialogue to the front. Use this to prepare your phase 3 trial and engage the FDA early to avoid delays.
◆ Coverage
3 sources · first reported 8 Oct 2026 · latest 9 Oct 2026
◆ Related on Wire
◆ Topics